Newron Pharmaceuticals SpA of Italy is to acquire NeuroNova AB, a privately-owned Swedish company that specialises in neurogenesis and which has early-stage compounds for Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
A preclinical drug combination treatment that is being positioned to treat dyskinesia has received €1.3 million in new funding from two Danish investment groups, SEED Capital and Novo Seeds, a unit of the Novo Nordisk Foundation.
Pharming Group NV of the Netherlands said that it has engaged two investment banks to help it explore strategic options that could lead to a merger, an equity investment or a sale. The company expects to issue an update in the third quarter.
Sanofi SA has announced regulatory filings in both the US and Europe for alemtuzumab (Lemtrada) to treat relapsing multiple sclerosis. The monoclonal antibody is already approved in the US for second-line CLL and trades as Campath.
Basilea Pharmaceutica Ltd is to receive £146 million upfront from Stiefel, a unit of GlaxoSmithKline Plc, for an eczema compound. It will use the proceeds to support the development and registration of its candidate antibiotic and antifungal drugs.
The US Food and Drug Administration has approved a new personalised medicine for HER2 positive breast cancer from Roche. But supplies of the drug will be limited pending the resolution of a manufacturing problem, according to the agency.
Zealand Pharma A/S and its partner, Sanofi SA, have presented further data supporting their candidate treatment for Type 2 diabetes, lixisenatide (Lyxumia). Lixisenatide is a glucagon-like peptide-1 agonist.
Eli Lilly and Company said that a Phase 2b study of baricitinib, a JAK inhibitor being developed for rheumatoid arthritis, reached its primary endpoint by showing a statistically significant response as measured by a scoring system.
GlaxoSmithKline Plc said that it has extended its $13 per share cash offer for Human Genome Sciences Inc until 17.00 Eastern Standard Time on 29 June. The tender offer was previously scheduled to expire at midnight on 7 June.
Affiris AG has started a Phase 1 study of a new vaccine for Parkinson’s disease which it says is aimed at modifying the disease rather than treating symptoms. The programme has received financial support from the Michael J Fox Foundation.